share_log

Barclays Maintains Overweight on NexImmune, Lowers Price Target to $2

Benzinga Real-time News ·  Aug 16, 2022 08:06

Barclays analyst Peter Lawson maintains NexImmune (NASDAQ:NEXI) with a Overweight and lowers the price target from $7 to $2.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment